Press Releases

Arch Biopartners Appoints Former Roche Executives Patrick Smith and Craig Rayner as Drug Development Advisors

TORONTO, ONARIO–(Marketwired – Sept. 17, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today Dr. Patrick Smith and Dr. Craig Rayner of d3 Medicine have been appointed drug development advisors to the Company.

In this capacity, Dr. Smith and Dr. Rayner will be providing expertise in all aspects of drug development for new drug products emerging from the Arch portfolio including pre-clinical planning, clinical trial design, cGMP manufacturing and liaising with government.

Dr. Smith, the former head of U.S. Clinical pharmacology for Roche, has more than 15 years of global drug development experience. He is a Research Professor at the State University of New York at Buffalo and has more than 80 peer reviewed publications in top tier journals. Dr. Smith has extensive knowledge in all aspects of drug development, with particular emphasis on innovative translational and quantitative approaches in early phase development to optimize speed and efficient proof of concept delivery.

Dr. Rayner has more than 15 years of drug development experience. He holds an Associate Professorship in Pharmaceutical Science at Monash University (Australia). Dr. Rayner’s past appointments include leadership roles in Clinical Pharmacology and Early Development (Roche), Clinical Development (CSL-Behring) and in Business Development as Global Scientific Due Diligence Leader (Roche). Dr. Rayner has extensive regulatory interaction experience with major health authorities. While at Roche, Dr. Rayner was accountable for numerous due diligences including that relating to the acquisition of Arius Research in 2008.

Dr. Smith and Dr. Rayner are currently directors of d3 Medicine, a global drug development firm they co-founded in 2012.

About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company’s lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma. The Company’s website address is:

For more information on the Company, please consult the other public documents filed on SEDAR at

About d3 Medicine

d3 Medicine was created to provide the biopharmaceutical industry, non-profit sector, and government agencies with access to a team of contemporary drug development experts. With a strong track record of delivering genuine commercial and therapeutic impact, d3’s team members are globally recognized as industry leaders. The company’s website address is:

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.

Press Release Archives